Log In Sign Up

GLP-1 Receptor Agonists: The Healthspan and Longevity Evidence

July 01, 2026

Reviewed

GLP-1 Receptor Agonists: The Healthspan and Longevity Evidence

GLP-1 receptor agonists behave like calorie-restriction mimetics — activating AMPK and SIRT1, restraining mTOR, and restoring autophagy — while protecting aged hearts, brains and muscle across model organisms. The healthspan case is strong; the maximum-lifespan case is not. This review separates what the literature has actually shown from what remains a preclinical promise.

This post is derived from a verified BioSkepsis research thread — every claim below is traceable to a PubMed source. View the research on BioSkepsis →

The geroscience case: GLP-1 agonists as calorie-restriction mimetics

The mechanistic argument for GLP-1RAs as geroprotectors rests on nutrient sensing. These agents upregulate the energy-deprivation sensors AMPK and SIRT1 while inhibiting the growth-promoting mTOR and insulin/IGF1 axes — the same rewiring that underlies calorie restriction, the most reproducible lifespan intervention in biology.

Downstream, this restores proteostasis. In primary human hepatocytes and murine liver, GLP-1R activation resolves steatosis and blunts ER-stress apoptosis by sustaining the chaperone GRP78 and suppressing CHOP, and it drives both macroautophagy and chaperone-mediated autophagy — measured as increased Beclin-1 and conversion of LC3-I to LC3-II [1]. In cardiomyocytes exposed to 33 mM glucose, exendin-4 and liraglutide partially restore peak shortening and ±dL/dt through an mTOR/ULK1-dependent autophagic mechanism [2]. The redox benefit is direct: GLP-1RAs lower mitochondrial ROS and whole-cell superoxide while recovering mitochondrial membrane potential in leukocytes from patients with type 2 diabetes [3].

The agents also act on cellular senescence itself. Exendin-4 protects vascular smooth muscle cells from angiotensin II-induced senescence via Nrf2, cutting oxidative stress and p53/p21 expression [35], and liraglutide attenuates high-glucose-induced senescence and oxidative damage in lung tissue [40]. This is mechanism, not metaphor — named sensors, named markers, named pathways.

A lifespan signal — in a worm

In C. elegans models of glucose-induced neurodegeneration, liraglutide (160 µmol/l) reduced oxidative stress by 29%, cut methylglyoxal-derived AGEs by 33%, and extended mean lifespan by 9% in an AKT1/FOXO-dependent manner [4]. It is the clearest direct lifespan result in the corpus — and it is invertebrate, which is exactly why it cannot be over-read.

Neuroprotection and cognitive healthspan: from C. elegans to dementia cohorts

The neuroprotective data are the strongest part of the preclinical story. In the APPswe/PS1ΔE9 mouse, liraglutide reduced cortical β-amyloid plaque count and dense-core plaques by 40–50% and halved activated microglia [5]. In senescence-accelerated SAMP8 mice, liraglutide restored T-maze memory retention and increased hippocampal CA1 pyramidal neuron numbers independent of weight loss [6]. In Parkinson's models, semaglutide protected substantia nigra dopaminergic neurons in the MPTP paradigm [16] and defended against 6-OHDA toxicity by enhancing autophagy and suppressing oxidative stress [17].

The human signal is associative but consistent. A pooled analysis of LEADER, SUSTAIN-6 and PIONEER 6 with a Danish nationwide cohort reported a dementia hazard ratio of 0.47 [7]. A large retrospective cohort of newer agents found lower dementia risk (HR 0.63) and lower all-cause mortality (HR 0.70) for semaglutide and tirzepatide [8]. An exploratory REWIND analysis showed dulaglutide cut substantive cognitive impairment by 14% [7]. These are real, sizeable effects — in people with diabetes or obesity, which is not yet the same as a general-population disease-modifying claim.

Cardiovascular protection independent of weight loss

GLP-1RAs act on the myocardium directly. Liraglutide pretreatment before experimental myocardial infarction reduced cardiac rupture and infarct size while modulating Akt, GSK3β, Nrf2 and HO-1 [9]. In a large-animal model of isolated coronary artery disease, oral semaglutide improved left ventricular ejection fraction and roughly doubled resting perfusion to the most ischemic territory (0.89 vs 0.41 mL/min/g), with less interstitial and perivascular fibrosis via activated AMPK and eNOS [10]. In patients, GLP-1RA treatment tracks with reduced carotid intima-media thickness and lower circulating ICAM-1 and VCAM-1 [3]; exendin-4 inhibits monocyte adhesion and attenuates atherosclerotic lesions independent of glucose lowering [18].

Cardioprotection you can count

In the infarction model, liraglutide reduced cardiac rupture to 12 of 60 animals versus 46 of 60 in controls, and shrank infarct size to 21 ± 2% from 29 ± 3% [9] — a structural effect, not a surrogate, and one that persisted independent of weight or glycemic change.

The evoke trials: semaglutide biomarkers in early Alzheimer's disease

The evoke and evoke+ phase 3 programme is the most ambitious test of GLP-1 neuroprotection in humans. Both are double-blind, placebo-controlled trials of oral semaglutide in early-stage symptomatic Alzheimer's disease, with a longitudinal plasma and CSF biomarker panel designed to detect disease modification rather than symptom masking [21]. Enrollment required amyloid abnormality by PET or CSF; the trials then track longitudinal change in core AD biomarkers and tau biology [21][22].

Neuroinflammation is a primary pharmacodynamic target. The panels monitor central and peripheral inflammation, motivated by evidence that GLP-1RAs push microglia and astrocytes toward homeostasis and reduce IL-1α, TNF-α and C1q [22][24], with preclinical inhibition of NF-κB and NLRP3 inflammasome signalling [23]. Systemic C-reactive protein — reliably lowered by semaglutide in other populations — is correlated against central readouts [24]. Beyond proteinopathy, the trials assay synaptic integrity (preclinically, GLP-1RAs preserve synaptophysin and PSD-95 and rescue Aβ-suppressed long-term potentiation), vascular and blood-brain-barrier integrity, and oxidative-stress markers [21][23][3]; the evoke+ arm deliberately enrolls participants with significant small-vessel pathology to probe vascular protection.

The caution is unavoidable. Reports indicate the semaglutide AD programme may have failed to meet its primary cognitive endpoints [23], and screening produced a high failure rate driven mainly by stringent cognitive cut-offs rather than biomarker negativity. Robust SAMP8 neuron rescue [6] has not yet become a proven human structural or clinical rescue [23]. A well-designed biomarker strategy does not guarantee a positive trial.

Muscle, bone and physical function: the body-composition tradeoff

Long-term GLP-1RA therapy produces a characteristic shift: absolute lean mass falls, but its proportion of body mass rises because fat is lost faster. In the SEMALEAN study of grade-3 obesity, semaglutide 2.4 mg dropped absolute lean mass by 3.0 kg at 7 months then stabilised, handgrip strength rose 4.1 kg by 12 months, and sarcopenic-obesity prevalence fell from 49% to 33% [25]. A SURMOUNT-1 subgroup showed tirzepatide reduced fat roughly three times more than lean — comparable to lifestyle and surgical weight loss [33]. A real-world cohort saw a larger lean loss above 3 kg [26], and in people with HIV, 24 weeks of semaglutide cut psoas volume by 9.3% while muscle fat fraction held steady [27]. Mechanistically, liraglutide and semaglutide suppress the muscle ubiquitin ligase Atrogin-1 and raise Myogenin via SIRT1 [11], and semaglutide-driven weight loss improved skeletal-muscle mitochondrial OXPHOS efficiency, an effect requiring intact cellular structure [34].

Bone tracks the mechanostat theory — resorb what is no longer loaded. Semaglutide 1.0 mg over 52 weeks raised the resorption marker P-CTX (estimated treatment difference 166.4 ng/L) and lowered areal BMD at lumbar spine (−0.018 g/cm²) and total hip (−0.020 g/cm²) versus placebo [28]; liraglutide 3.0 mg alone reduced hip and spine BMD more than exercise alone despite similar weight loss, while adding vigorous exercise preserved BMD even at greater weight loss [29]. The dose matters: low-dose liraglutide 1.2 mg raised the formation marker P1NP by 16% and prevented bone-content loss in weight-reduced women [30]. At the population scale, a cohort of over 216,000 people found no association between GLP-1RA use and fracture [31], and an umbrella review judged the fracture effect neutral [38] — though switching from a DPP-4 inhibitor to a GLP-1RA produced a steeper spine-BMD decline (−0.028 vs −0.019 g/cm²) [32].

Function, not scan density, is what improves. In obesity-related HFpEF, semaglutide extended 6-minute walk distance by 21.5 m versus 1.2 m on placebo and improved KCCQ symptom and physical-limitation scores [33]. In the HIV cohort, gait speed and chair-rise held despite muscle loss, and slow-gait prevalence fell from 63% to 46% [27].

Body-composition and bone effects by agent and dose
Finding Agent / dose Direction
Absolute lean mass Semaglutide 2.4 mg [25] −3.0 kg, then stable
Sarcopenic obesity Semaglutide 2.4 mg [25] 49% → 33%
Handgrip strength Semaglutide 2.4 mg [25] +4.1 kg
Spine BMD Semaglutide 1.0 mg [28] −0.018 g/cm²
Bone formation (P1NP) Liraglutide 1.2 mg [30] +16%
Fracture risk Class, 216k cohort [31][38] Neutral
6-min walk (HFpEF) Semaglutide 2.4 mg [33] +21.5 m

Where the evidence breaks down: lifespan, withdrawal and unresolved contradictions

Four gaps matter more than the headlines. First, maximum lifespan in healthy, non-diabetic mammals is unproven — GLP-1RAs consistently delay functional decline in heart, brain and muscle, but a survival-curve extension in wild-type animals has not been demonstrated. Second, brain access differs by agent: exendin-4 and certain dual agonists cross the blood-brain barrier measurably, whereas the acylated agents liraglutide and semaglutide show limited or slow influx in specific models [14] — a pharmacokinetic caveat that complicates extrapolating rodent CNS results across the class.

Third, the clinical Parkinson's picture is unsettled. Systematic review associates exenatide and liraglutide with improved MDS-UPDRS Part III scores and possible slowing [14], and a dual GLP-1/GIP agonist (DA-CH5) outperformed single agonists in the MPTP model [41] — yet large-scale data for newer agents have not consistently shown reduced PD risk [8]. Fourth, intermittent dosing can be worse than none. In aged, obese UM-HET3 mice, repeated liraglutide withdrawal caused drug tolerance and hyperleptinemia; fat mass returned during withdrawal but lean mass only partly recovered, shifting body composition unfavourably [12]. Continuous administration appears necessary to prevent aging-associated sarcopenia.

Two interpretive contradictions remain live. The bone data conflict — liraglutide raises formation markers [30] while semaglutide raises resorption without changing formation [28] — and the direct head-to-head comparison in a bone-health context is missing. And standard insulin-sensitivity indices misbehave on incretins: some semaglutide cohorts saw fasting insulin hold or rise despite weight loss, leaving HOMA2-IR unchanged and arguably unreliable in this setting [37]. The adiponectin paradox compounds this, since elevated adiponectin in older adults is linked to both restorative and adverse outcomes [15].

The withdrawal trap

Cycling on and off is not a neutral choice. In aged UM-HET3 mice — the strain used by the NIA Interventions Testing Program — repeated GLP-1RA withdrawal induced hyperleptinemia and a failure to restore lean mass during weight regain, potentially accelerating sarcopenia [12]. For older adults, where lean mass is the currency of independence, that is the finding to weigh most heavily.

Evidence tiers — what GLP-1 agonists have and haven't shown for aging
Claim Strength Best evidence
Modulates hallmarks of aging (autophagy, senescence, mtROS) Robust (preclinical) [1][3][35][40]
Weight-loss-independent cardioprotection Robust [9][10]
Lower dementia incidence Suggestive (associative) [7][8]
Preserved physical function despite lean loss Robust (clinical) [25][27][33]
Neutral fracture risk Robust (epidemiologic) [31][38]
Structural neuro-rescue in humans Unproven [23] (evoke endpoint miss)
Reduced Parkinson's risk (newer agents) Unproven [8][14]
Maximum-lifespan extension in healthy mammals Not demonstrated —

How GLP-1 agonists compare with metformin and rapamycin

GLP-1RAs are best read as convergent with, not competitive against, the established geroprotectors. They share metformin's core levers — AMPK activation and macroautophagy — and liraglutide attenuates NAFLD through AMPK/ACC signalling while inhibiting ferroptosis, the same axis metformin engages [36][1]. The relationship runs both ways: part of metformin's action depends on stimulating endogenous GLP-1 secretion [20], so the two pathways are mechanistically entangled rather than redundant.

On outcomes, EXSCEL showed exenatide reduced all-cause mortality and cardiovascular events, with additive benefit alongside SGLT2 inhibitors [19], and modelling estimates that combining SGLT2 inhibitors, GLP-1RAs and a nonsteroidal MRA delivers substantial lifetime cardiovascular, kidney and mortality benefit over conventional care [13]. The clean rapamycin-style comparison — lifespan extension in healthy wild-type animals — is where GLP-1RAs still have no equivalent result to report.

Ongoing trials are beginning to test the aging question directly in non-obese and non-diabetic populations. A phase 2 study evaluates tirzepatide on muscle and vascular health in older adults (NCT06811324); an early-phase study investigates microdosed GLP-1 for immunological health, heart-rate variability and self-reported quality of life (NCT07092605); and a dedicated geroscience trial assesses semaglutide and tirzepatide against epigenetic and genetic markers of aging (NCT07293325). For a broader map of how these mechanisms connect, the curated BioSkepsis Research Hub Pathways threads trace the molecular links across the same literature.

What the GLP-1 aging evidence means for researchers and clinicians

BioSkepsisGeroscience researchers tracking incretin biology

This is a fast-moving, hype-adjacent field where the literature turns over quarterly and the gap between rodent rescue and human endpoints is the whole story. Citation-grounded synthesis over full text — with every claim traceable to a PMID and evidence tiered rather than asserted — is what keeps a review honest. A general-purpose model will happily generalise a worm lifespan result to humans; a retrieval-grounded system tells you it is invertebrate and stops there.

Clinicians prescribing for older adults

The actionable signals are body composition and continuity. Expect absolute lean mass to fall while function improves — but avoid casual on-off cycling, which in aged mice left a worse composition than no treatment [12]. Fracture risk is neutral at the population level [31][38], yet resistance exercise measurably preserves BMD during weight loss [29] and is the cheapest co-intervention available.

Trial designers and endpoint committees

evoke is the cautionary case: a comprehensive plasma and CSF biomarker panel [21][22] did not rescue a programme that appears to have missed its cognitive primary [23]. Powering on cognition, not biomarkers, and anticipating high screen-failure from stringent cognitive cut-offs are the design lessons for the next generation of neuro-metabolic trials.

The longevity-curious reader

The strongest honest claim is healthspan, not lifespan — better function in aging organs, not a demonstrated longer maximum life. Treat any "anti-aging" framing that skips the muscle, bone and withdrawal caveats as marketing, and read the evidence tier before the headline.

Frequently asked questions about GLP-1 agonists and aging

Do GLP-1 receptor agonists like Ozempic actually slow aging?

They mitigate several hallmarks of aging in preclinical models — chronic inflammation, impaired autophagy, mitochondrial dysfunction and cellular senescence — and improve organ-level function in aged hearts, brains and muscle. That is healthspan extension. Direct extension of maximum lifespan in healthy, non-diabetic mammals has not been demonstrated, so "slows aging" is supported for function, not yet for lifespan.

Does semaglutide reduce dementia risk?

Observational and pooled-trial data are encouraging. A pooled analysis of LEADER, SUSTAIN-6 and PIONEER 6 plus a Danish nationwide cohort reported a dementia hazard ratio of 0.47 [7], and a large retrospective cohort of semaglutide and tirzepatide users found a dementia HR of 0.63 and an all-cause mortality HR of 0.70 [8]. These are association-level findings in people with diabetes or obesity, not proof of a disease-modifying effect in the general population.

Do GLP-1 drugs cause muscle loss in older adults?

Absolute lean mass typically falls during rapid weight loss — around 3 kg in the SEMALEAN study [25] and up to ~9% of psoas volume over 24 weeks in one HIV cohort [27]. But lean mass falls less than fat mass, so its proportion rises, and objective function usually improves: handgrip strength increased and sarcopenic-obesity prevalence fell from 49% to 33% in SEMALEAN. The real concern is intermittent use — cyclical withdrawal restored fat but not lean mass in aged mice [12].

Do GLP-1 receptor agonists weaken bones?

The effect is dose- and context-dependent, consistent with the mechanostat theory: bone remodels down when mechanical loading drops with weight loss. Semaglutide 1.0 mg raised the resorption marker P-CTX and lowered areal BMD at spine and hip over 52 weeks [28], while low-dose liraglutide 1.2 mg raised the formation marker P1NP and prevented bone-content loss [30]. A 216,000-person cohort found no association with fracture risk [31], and an umbrella review concluded the fracture effect is neutral [38].

Did the semaglutide Alzheimer's trials (evoke and evoke+) work?

The evoke and evoke+ phase 3 trials tested oral semaglutide in early-stage symptomatic Alzheimer's disease with a longitudinal plasma and CSF panel spanning core amyloid and tau markers, neuroinflammation, and synaptic and vascular integrity [21][22]. Reports indicate the programme may have failed to meet its primary cognitive endpoints [23] — a reminder that robust rodent neuroprotection has not translated into a proven structural or clinical rescue in humans.

Are GLP-1 receptor agonists better than metformin for longevity?

They are convergent rather than competing. Both activate AMPK and induce macroautophagy, and part of metformin's action runs through stimulation of endogenous GLP-1 secretion [20]. Neither has demonstrated lifespan extension in healthy wild-type animals. Modelling suggests combining GLP-1 agonists with SGLT2 inhibitors and a nonsteroidal MRA yields substantial lifetime cardiovascular and mortality benefit over conventional care [13].

Should GLP-1 drugs be stopped and restarted, or taken continuously?

The aging-relevant evidence favours continuity. In aged, obese UM-HET3 mice, repeated withdrawal cycles produced drug tolerance, hyperleptinemia and a failure to restore lean mass during weight regain, shifting body composition unfavourably [12]. This is a mouse finding, but it argues against casual on-off cycling in older adults where preserving lean mass matters most.

Trace every claim in this post to its source

This review was built from a BioSkepsis research thread that read the full text of 40M+ biomedical papers and grounded each synthesis in a citation you can open. Where the evidence is thin, it says so — rather than smoothing over the gap the way an ungrounded model would. Ask your own question and get an answer you can check.

Start free

Sources

  1. Sharma S, et al. GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the UPR and Promoting Macroautophagy. PLoS ONE. 2011. PMID 21957486.
  2. Yu W, Zha W, Ren J. Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy. Oxid Med Cell Longev. 2018. PMID 29849901.
  3. Luna-Marco C, et al. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol. 2023. PMID 37591012.
  4. Wongchai K, et al. Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration. Horm Metab Res. 2016. PMID 25951323.
  5. McClean PL, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci. 2011. PMID 21525299.
  6. Hansen HH, et al. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2015. PMID 25869785.
  7. Nørgaard CH, et al. Treatment with GLP-1 receptor agonists and incidence of dementia: pooled double-blind RCTs and nationwide registers. Alzheimers Dement (N Y). 2022. PMID 35229024.
  8. Lin H, et al. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2025. PMID 40663350.
  9. Noyan-Ashraf MH, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009. PMID 19151200.
  10. Stone C, et al. Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2025. PMID 39665144.
  11. Xiang J, et al. GLP-1RA Liraglutide and Semaglutide Improve Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diabetes Metab Syndr Obes. 2023. PMID 37602204.
  12. Jiang N, et al. Repeated Withdrawal of a GLP-1R Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM-HET3 Mice. Aging Cell. 2025. PMID 40960340.
  13. Neuen BL, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA. Circulation. 2023. PMID 37952217.
  14. Kalinderi K, et al. GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease. Int J Mol Sci. 2024. PMID 38612620.
  15. McGregor ER, et al. Adiponectin and aging: mechanistic insights, clinical paradox, and therapeutic horizons. Ageing Res Rev. 2026. PMID 41690624.
  16. Zhang L, et al. Neuroprotective effects of the novel GLP-1 long-acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018. PMID 30017231.
  17. Liu D, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022. PMID 35873704.
  18. Arakawa M, et al. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by Exendin-4. Diabetes. 2010. PMID 20068138.
  19. Clegg LE, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment on mortality and cardiovascular and renal outcomes: insights from EXSCEL. Cardiovasc Diabetol. 2019. PMID 31640705.
  20. Bahne E, et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight. 2018. PMID 30518693.
  21. Cummings JL, et al. evoke and evoke+: design of two large-scale phase 3 studies of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Res Ther. 2025. PMID 39780249.
  22. Scheltens P, et al. Baseline characteristics from evoke and evoke+: two phase 3 RCTs of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2026. PMID 41522368.
  23. Athauda D, et al. The promise of GLP-1 receptor agonists for neurodegenerative diseases. J Clin Invest. 2026. PMID 41697753.
  24. Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025. PMID 41178710.
  25. Alissou M, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2025. PMID 41068996.
  26. Pantanetti P, et al. Changes in body weight and composition, metabolic parameters, and quality of life with subcutaneous semaglutide in real-world practice. Front Endocrinol. 2024. PMID 39015186.
  27. Ditzenberger GL, et al. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clin Infect Dis. 2025. PMID 39046173.
  28. Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a phase 2 trial. EClinicalMedicine. 2024. PMID 38737002.
  29. Jensen SBK, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Netw Open. 2024. PMID 38916894.
  30. Iepsen EW, et al. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. J Clin Endocrinol Metab. 2015. PMID 26043228.
  31. Driessen JHM, et al. Bone Fracture Risk is Not Associated with the Use of GLP-1 Receptor Agonists: A Population-Based Cohort Analysis. Calcif Tissue Int. 2015. PMID 25894068.
  32. Huang C, Mao T, Hwang S. Effects of Switching from DPP-4 Inhibitors to GLP-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients. Diabetes Metab Syndr Obes. 2023. PMID 36760582.
  33. Kosiborod M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023. PMID 37622681.
  34. Choi RH, et al. Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle. Obesity (Silver Spring). 2025. PMID 40254778.
  35. Zhou T, et al. Activation of Nrf2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence. Am J Physiol Cell Physiol. 2016. PMID 27488664.
  36. Guo T, et al. Liraglutide attenuates T2DM-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023. PMID 37770820.
  37. Anyiam O, et al. Metabolic effects of very-low-calorie diet, Semaglutide, or combination, in individuals with type 2 diabetes. Clin Nutr. 2024. PMID 38996661.
  38. Kong F, et al. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nat Commun. 2026. PMID 41501059.
  39. Zhang X, et al. Liraglutide ameliorates inflammation and apoptosis via inhibition of RAGE signaling in AGE-induced chondrocytes. BMC Musculoskelet Disord. 2024. PMID 39080620.
  40. Pu Z, et al. The Effect of Liraglutide on Lung Cancer and Its Potential Protective Effect on High Glucose-Induced Lung Senescence and Oxidative Damage. Front Biosci (Landmark). 2023. PMID 37919054.
  41. Zhang L, et al. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease. J Parkinsons Dis. 2020. PMID 31958096.
  • Trial registrations (ClinicalTrials.gov, not PubMed):
  • NCT06811324 — tirzepatide, muscle and vascular health in older adults with obesity (phase 2, recruiting).
  • NCT07092605 — microdosed GLP-1 for immunological health, heart-rate variability and quality of life (early phase, enrolling).
  • NCT07293325 — semaglutide and tirzepatide for genetic/epigenetic aging delay (recruiting).